Oliver Chen, TD Cowen senior retail analyst, joins 'Money Movers' to discuss Wall Street's reaction to Walmart's quarterly ...

TD Cowen raised the firm’s price target on Analog Devices (ADI) to $280 from $260 and keeps a Buy rating on the shares. The firm said they ...

CNBC’s Eamon Javers and TD Cowen’s Roman Schweizer, join 'The Exchange' to discuss Trump's comments on halving defense ...

Charles Schwab (NYSE:SCHW – Get Free Report) was upgraded by equities researchers at TD Cowen from a “hold” rating to a “buy” ...

TD Cowen analyst Dan Brennan lowered the firm’s price target on NeoGenomics (NEO) to $19 from $20 and keeps a Buy rating on the shares. The ...

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates ...

TD Cowen was established in 1918 as a bond trading firm and quickly expanded into clearing and execution services. By the 1970s, it had carved a niche in railroad bonds and grown a solid research ...

TriNet Group (NYSE:TNET – Get Free Report) was downgraded by equities research analysts at TD Cowen from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday, Ratings ...

Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, ...

TD Cowen initiated coverage of Centessa (CNTA) with a Buy rating and no price target The firm says the company’s ORX750 has a “best in class profile as a transformative therapy” in excessive ...

Investors and the general public are invited to listen to a live webcast of the presentation through the "Investors" section ...